LUCID CAPITAL MARKETS Initiates Coverage On Microbot Medical with Buy Rating, Announces Price Target of $4
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Microbot Medical (NASDAQ:MBOT) with a Buy rating and announces Price Target of $4.
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Microbot Medical (NASDAQ:MBOT) with a Buy rating and announces Price Target of $4.